Nykode Therapeutics As (VACBF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the NICO Therapeutics Q1 2025 Financial Results Presentation. At this time, all participants are in listen-only mode. If anyone would require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may ask a question at any time by typing it into the Ask a Question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to introduce our host, Michael Ensig, CEO of Nyco Therapeutics. Please go ahead, Michael. Thank you very much, Kevin. And also from my side, a very warm welcome to all participants to this webcast for our first quarter results and updates from the business. A quick reminder of our forward-looking statements. Assuming you're all familiar with this kind of forward-looking statements, we will move on. As usual, I am very happy to have with me here today, André Frederiksen, our Chief Scientific Officer and Head of Business Development and Co-Founder, as well as Hal Guren, our Chief Financial Officer. And together we'll try to take you through a deep dive in the business update and the financial numbers for the first quarter. So, happy to report that we have finalized the organizational streamlining that we set out to do and announced in the beginning of the year we have finalized that in the first quarter and will maintain a very strong focus on cost control in the company going forward which will in turn allow us to execute on our future priorities which we look forward to update you on in the near future We have also had Susanne Stauffer selected as Chair of the Board at the Extraordinary General Assembly on the 23rd of April. We have included a very brief bio on the right of this slide here, which we will...